With Allergan deal sealed, Teva turns its attention to branded M&A | Fierce Pharma
Teva in talks to buy Allergan big generic-drug unit: WSJ | Reuters.com
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says | Ctech
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
Teva faces fresh shareholder showdown over management structure | Financial Times
La farmacéutica Teva ofrece US$40.000 millones por Mylan - WSJ
Teva lanza oferta por Mylan de US$82 por acción
The Wall Street Journal' preveu "l'acceleració" de la ruptura entre Catalunya i Espanya
Teva, denying 'any liability,' set aside $646M for opioid settlements. Here's why | Fierce Pharma
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges - WSJ
Israeli drug manufacturer Teva at center of anti-trust lawsuit brought by 44 states - Jewish Telegraphic Agency
With Teva Bid Off the Table, Mylan's Stock In 'Show-Me' Mode - WSJ
PHARMACOSERÍAS Marketing Farmacéutico/Pharmaceutical Marketing: TEVA: Camino dificil para nuevo CEO
Teva to Buy Generics Distributor Anda From Allergan for $500 Million - WSJ
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges - WSJ
Teva, distributors sidestep Ohio opioid trial with last-minute deal: WSJ | Fierce Pharma
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
FDA's Call on Migraine Drug Could Be Trouble for Teva | Barron's
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva to Buy Allergan Generics for $40.5 Billion - WSJ
Teva Tries to Put an End to the Opioid Wars - WSJ
